comprehensive -WSS

comprehensive

author：fashion 2025-09-29 22:53:33 - browse：8387

Doctor holding a clipboard. -- health coverage from STAT — Adobe

The momentum around weight loss drugs is about to get even bigger in the wake of Novo Nordisk’s announcement that its semaglutide drug Wegovy cut the risk of cardiovascular disease by 20% in its large SELECT trial.

The full results of the study, funded by Novo, will be presented at the American Heart Association meeting in November. Doctors and researchers say they expect the findings to have a big impact on how clinicians approach the treatment of both obesity and cardiovascular disease, as well as increase the likelihood that prescriptions for obesity drugs will be covered by insurance.

But experts who spoke with STAT also cautioned that the long-term safety and efficacy of Wegovy and other weight loss drugs remain unknown. The SELECT study has yet to be peer-reviewed, and not enough information is yet available to make independent assessments of the results.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： The 10 drugs up first for Medicare price negotiation

WSS

AstraZeneca chief proposes a novel edit to the drug pricing bill

'Make People Better': The CRISPR babies story you probably don't know

Amazon on where the company's health care bets are headed next

ADCs take center stage as promising cancer treatments

What American doctors can learn from their Israeli counterparts

Stem cell treatment guidelines are released by FDA

focus

comprehensive

focus

Psychedelics group wrestles with new pharma identity

Covid hospitalizations on the rise, Humana says

Trump demands the U.S. pay no more for drugs than other countries … again

The 10 drugs up first for Medicare price negotiation

Heart attack and stroke risk calculators need revising

Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Trump surgeon general acknowledges mistakes during Covid

Malaria cases in Florida and Texas: Here’s what you need to know

How to fix cancer clinical trials' diversity problem

entertainment

Advances in CAR

Why Novartis is changing the name of its research labs

STAT Summit: Meghan O’Rourke on making chronic illness visible

Biotech execs pursue obesity drug boom: ‘It’s the early innings’

J&J lung cancer data amount to new salvo against AstraZeneca

Trump surgeon general acknowledges mistakes during Covid

leisure time

hotspot

knowledge

hotspot